Maria Luisa Landi

TL;DR: To investigate whether previous treatment with bromocriptine or quinagolide impairs a subsequent response to long-term cabergoline (CAB) treatment, 110 patients with macroprolactinoma were studied.

TL;DR: After 24 months, PRL normalization and tumor shrinkage after CAB and BRC treatments, respectively, were obtained in 82.1% and 46.4% of macroprolactinomas and in 90% vs. 56.8% of microprolACTinomas.

TL;DR: The medical treatment with dopaminergic compounds is effective and safe in patients with prolactinoma with onset in childhood, allowing preservation of the anterior pituitary function.

TL;DR: Cabergoline (CAB), a long-lasting dopamine-agonist, specific for the D2 receptor, is effective in normalizing serum PRL levels in most patients with microprolactinoma or idiopathic hyperProlactinemia, and this open-label study investigated whether this drug was effective in producing tumor shrinkage, as well as innormalizingPRL levels.

TL;DR: The data from this study in combination with previous reports can exclude a congenital malformation risk greater than 10% associated with pregnancy exposure to cabergoline.